What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors? | Zendy

Maissaa Janbain | Zendy; Steven W. Pipe | Zendy

Open Access

What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors?

Author(s) -

Maissaa Janbain,

Steven W. Pipe

Publication year - 2016

Publication title -

hematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.321

H-Index - 91

eISSN - 1520-4391

pISSN - 1520-4383

DOI - 10.1182/asheducation-2016.1.648

Subject(s) - titer , medicine , immune tolerance , recombinant dna , immune system , product (mathematics) , immunology , biology , antibody , genetics , gene , mathematics , geometry

A 10-year-old boy presents with a history of severe hemophilia A and high-titer inhibitor that had failed high-dose immune tolerance induction (ITI) with a recombinant factor VIII (rFVIII) product and a plasma-derived FVIII product. You are asked by his mother whether he should be tried on ITI with an extended half-life product, in particular, consideration of a rFVIIIFc concentrate.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research